Pharmacosmos As Patent-Cliff Exposure & CMS Drug Spending Portfolio

Pharmacosmos As (US): 2 reconciled FDA prescription therapies, $20.6M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2036-01-01
2024 CMS Total Public Spend$20.6M
2024 Medicare Part D Spend$99K
2024 Medicaid Spend$20.5M
California HCAI SB 17 Filings7 WAC filings (max 39.7% 2-yr change)